|Classification and external resources|
Campomelic dysplasia (CMD) is a rare genetic disorder characterized by bowing of the long bones and many other skeletal and extraskeletal features.  It is frequently lethal in the neonatal period due to respiratory insufficiency, but the severity of the disease is variable, and some patients survive into adulthood.  The name is derived from the Greek roots campo (or campto), meaning bent, and melia, meaning limb. An unusual aspect of the disease is that up to two-thirds of affected 46,XY genotypic males display a range of intersex genital ambiguities or may even develop as normal phenotypic females.  An atypical form of the disease with absence of bowed limbs is called, prosaically, acampomelic campomelic dysplasia (ACD) and is found in about 10% of patients, particularly those surviving the neonatal period. 
Clinical features and screening
While the definitive presentation of the disease is a patient having bowed lower limbs and sex reversal in 46,XY males, there are other clinical criteria that can be used, absent these characteristics, to make the diagnosis. Patients may present with underdeveloped shoulder blades, shortened and angulated lower limbs, a vertically oriented and narrow pelvis, an enlarged head, an undersized jaw, cleft palate, flat nasal bridge, low set ears, club feet, dislocated hips, 11 pairs of ribs instead of 12, or bone abnormalities in the neck and spine. Respiratory distress can be caused by an underdeveloped trachea which collapses on inhalation or by insufficient rib cage development.
In utero sonographic diagnosis is possible when characteristic features such as bilateral bowed femurs and tibia, clubbed feet, prominent curvature of the neck, a bell-shaped chest, pelvic dilation, and/or an undersized jaw are apparent  Radiographic techniques are generally used only postnatally and also rely on prototypical physical characteristics. 
Genetic screening is also typically done postnatally, including PCR typing of microsatellite DNA and STS markers as well as comparative genomic hybridization (CGH) studies using DNA microarrays.  In some cases PCR and sequencing of the entire SOX9 gene is used to diagnose CMD.  Many different translocation breakpoints and related chromosomal aberrations in patients with CMD have been identified. 
CMD is caused by chromosomal abnormalities, generally spontaneously arising or de novo mutations, in or around the gene SOX9 on the long arm of chromosome 17, specifically at position 17q24.  The SOX9 gene codes for a protein transcription factor which, when expressed at the embryonic stage, plays an important role in determining sexual characteristics and greatly influences skeletal development.  When the SRY gene of the Y chromosome is expressed in human embryos, a cascade of gene interactions controlled by SOX9 begins and ultimately leads to male gender. 
Numerous mutations have been identified involving the SOX9 gene that cause some form of CMD.  Any mutation within the coding region of SOX9 can cause campomelic dysplasia and 75% of the reported mutations lead to sex reversal. Four major classes of heterozygous SOX9 mutations can cause CMD: amino acid substitutions in the HMG-box, truncations or frameshifts that alter the C-terminal end, mutations at the splice junction, and chromosomal translocations. Additionally, mutations upstream from SOX9 can also cause CMD. Several researchers have reported cis-acting control elements upstream of SOX9. Translocation breakpoints scattered over 1Mb proximal to SOX9 indicate the presence of an extended control region.
The lack of correlation between specific genetic mutations and observed phenotype, particularly with regard to sex reversal, give clear evidence of the variable expressivity of the disease. Milder forms of the disease, seen in those who live beyond the neonatal period and those with ACD, may be attributable to somatic mosaicism—particularly for those with mutations within the SOX9 coding region.  Chromosomal aberrations in the upstream control regions or residual activity of the mutant SOX9 protein could also be responsible for the milder forms of the disease. Long-term survivors of CMD are significantly more likely to have translocation and inversion mutations upstream of SOX9 rather than mutations in the SOX9 coding region itself.
Incidence and prognosis
Campomelic dysplasia has a reported incidence of 0.05-0.09 per 10000 live births. In nearly 95% of the cases, death occurs in the neonatal period due to respiratory distress, generally related to small chest size or insufficient development of the trachea and other upper airway structures.
Among survivors of CMD, the skeletal malformations change over time to include worsening scoliosis or kyphosis resulting in decreased trunk size relative to the limb length.  Neurological damage is also often seen including mental retardation and deafness.  Even among survivors of the prenatal period, CMD patients have shortened life spans due to lifelong respiratory issues. Those patients with ambiguous genitalia or sex reversal at birth, of course, maintain that state, and are either sterile or have reduced fertility.
- S. Mansour, C. Hall, M. Pembrey and I. D. Young (1995). "A clinical and genetic study of campomelic dysplasia". J Med Genet 32 (6): 415–420. doi:10.1136/jmg.32.6.415. PMC 1050480. PMID 7666392.
- V.M. Wunderle, R. Critcher, N. Hastie et al. (1998). "Deletion of long-range regulatory elements upstream of SOX9 causes campomelic dysplasia". PNAS 95 (18): 10649–10654. doi:10.1073/pnas.95.18.10649. PMC 27949. PMID 9724758.
- T. Wagner, et. al. (1994). "Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9". Cell 79 (6): 1111–1120. doi:10.1016/0092-8674(94)90041-8. PMID 8001137.
- S. Mansour, A.C. Offiah, S. McDowall, et. al. (2002). "The phenotype of survivors of campomelic dysplasia". J Med Genet 39 (8): 597–602. doi:10.1136/jmg.39.8.597. PMC 1735206. PMID 12161603.
- K. Eger (2005). "Campomelic Dysplasia". J Diag Medical Sonography 21 (4): 345–349. doi:10.1177/8756479305278970.
- J. Goyal, A. Gupta and V. Shah (2011). "Campomelic dysplasia". Indian J Hum Genet 17 (3): 247–248. doi:10.4103/0971-6866.92085. PMC 3277002. PMID 22346005.
- R. Pop, C. Conz, K.S. Lindenberg, et. al. (2004). "Screening of the 1 Mb SOX9 59 control region by array CGH identifies a large deletion in a case of campomelic dysplasia with XY sex reversal". J Med Genet 41 (4): e47. doi:10.1136/jmg.2003.013185. PMC 1735745. PMID 15060123.
- H.Y. Kim, C.H. Yoon, G.H. Kim, et. al. (2011). "A Case of Campomelic Dysplasia without Sex Reversal". J Korean Med Sci 26 (1): 143–145. doi:10.3346/jkms.2011.26.1.143.
- N.L.M. Sobreira, V. Gnanakkan, M. Walsh, et. al. (2011). "Characterization of complex chromosomal rearrangements by targeted capture and next-generation sequencing". Genome Res 21 (10): 1720–1727. doi:10.1101/gr.122986.111. PMC 3202288. PMID 21890680.
- S. Ninomiya, M. Isomura, K. Narahara, Y. Seino and Y. Nakamura (1996). "Isolation of a testis-specific cDNA on chromosome 17q from a region adjacent to the breakpoint of t(12;17) observed in a patient with acampomelic campomelic dysplasia and sex reversal". Hum Mol Genet 5 (1): 69–72. doi:10.1093/hmg/5.1.69. PMID 8789441.
- James J. Cox, Lionel Willatt, Tessa Homfray, C. Geoffrey Woods (2011). "A SOX9 Duplication and Familial 46,XX Developmental Testicular Disorder". N Engl J Med 364 (1): 91–93. doi:10.1056/NEJMc1010311. PMID 21208124.
- Jobst Meyer, et. al. (1997). "Mutational analysis of the SOX9 gene in campomelic dysplasia and autosomal sex reversal: lack of genotype/phenotype correlations". Hum Mol Genet 6 (1): 91–98. doi:10.1093/hmg/6.1.91. PMID 9002675.
- D. Pfeifer, R. Kist, K. Dewar, K. Devon, E.S. Lander, B. Birren, L. Korniszewski, E. Back, G. Scherer (1999). "Campomelic dysplasia translocation breakpoints are scattered over 1 Mb proximal to SOX9: evidence for an extended control region". Am J Hum Genet 65 (1): 111–124. doi:10.1086/302455. PMC 1378081. PMID 10364523.
- S. Corbani, E. Chouery, B. Eid, et. al. (2010). "Mild Campomelic Dysplasia: Report on a Case and Review". Mol Syndromol 1 (4): 163–168. doi:10.1159/000322861. PMC 3042119. PMID 21373255.